000028
vs
Shanghai Composite
Over the past 12 months, has underperformed Shanghai Composite, delivering a return of -8% compared to the Shanghai Composite's 10% growth.
Stocks Performance
000028 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
![]() |
Mckesson Corp
NYSE:MCK
|
|
US |
![]() |
Cencora Inc
NYSE:COR
|
|
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
US |
![]() |
Cardinal Health Inc
NYSE:CAH
|
|
US |
![]() |
Henry Schein Inc
NASDAQ:HSIC
|
|
KR |
![]() |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
|
CN |
![]() |
Sinopharm Group Co Ltd
HKEX:1099
|
|
CN |
![]() |
Huadong Medicine Co Ltd
SZSE:000963
|
|
CN |
![]() |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
|
IT |
![]() |
Amplifon SpA
MIL:AMP
|
Performance Gap
000028 vs Shanghai Composite
US |
![]() |
Mckesson Corp
NYSE:MCK
|
|
US |
![]() |
Cencora Inc
NYSE:COR
|
|
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
US |
![]() |
Cardinal Health Inc
NYSE:CAH
|
|
US |
![]() |
Henry Schein Inc
NASDAQ:HSIC
|
|
KR |
![]() |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
|
CN |
![]() |
Sinopharm Group Co Ltd
HKEX:1099
|
|
CN |
![]() |
Huadong Medicine Co Ltd
SZSE:000963
|
|
CN |
![]() |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
|
IT |
![]() |
Amplifon SpA
MIL:AMP
|
Performance By Year
000028 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
![]() |
Mckesson Corp
NYSE:MCK
|
|
US |
![]() |
Cencora Inc
NYSE:COR
|
|
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
US |
![]() |
Cardinal Health Inc
NYSE:CAH
|
|
US |
![]() |
Henry Schein Inc
NASDAQ:HSIC
|
|
KR |
![]() |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
|
CN |
![]() |
Sinopharm Group Co Ltd
HKEX:1099
|
|
CN |
![]() |
Huadong Medicine Co Ltd
SZSE:000963
|
|
CN |
![]() |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
|
IT |
![]() |
Amplifon SpA
MIL:AMP
|
Competitors Performance
China National Accord Medicines Corp Ltd vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
![]() |
Schlumberger NV
NYSE:SLB
|
|
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
![]() |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
|
US |
R
|
Reddit Inc
NYSE:RDDT
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
![]() |
Halliburton Co
NYSE:HAL
|
|
LU |
![]() |
Tenaris SA
MIL:TEN
|
|
IN |
![]() |
Jio Financial Services Ltd
NSE:JIOFIN
|
China National Accord Medicines Corp Ltd
Glance View
China National Accord Medicines Corp Ltd, nestled within the bustling healthcare landscape of China, operates at the heart of the pharmaceutical distribution and retail sectors. Established with the goal of ensuring that essential medicines and healthcare services are accessible to the vast Chinese population, the company has built an extensive distribution network. This network efficiently links manufacturers with hospitals, clinics, and pharmacies, making certain that a myriad of pharmaceutical products reach their intended destinations. By leveraging a combination of logistical prowess and vast geographical coverage, the company adeptly navigates the complexities of supply chain management, underscoring its role as a critical player in China's healthcare infrastructure. Beyond distribution, China National Accord Medicines also capitalizes on the booming retail pharmaceuticals market through its chain of pharmacies. These retail outlets serve as direct points of sale to consumers, offering both prescription and over-the-counter medications, alongside health consultation services. This dual focus on both wholesale distribution and retail outlets enables the company to capture value across the supply chain, from manufacturer to end-user. The strategic alignment of its operations streamlines efficiency and generates revenue, sustaining its growth amid a fiercely competitive and rapidly evolving market. Through this integrated approach, the company solidifies its position as a crucial conduit in the delivery of healthcare solutions across China.